QTTB · Healthcare · $195M mkt cap · FY2025 filings · Shallow moat ·
Doesn't clear the bar
2021–2025 (latest 4 aligned FYs; v3 window cap 5): revenue $34M to $53.7M, increasing; diluted EPS -1.73 to 2.42, increasing. 1 fiscal year was not jointly reported; CAGR uses the full 4-year elapsed span. Latest-filed diluted EPS remains usable for Business Trend, but an integer share-count change lacks enough evidence to confirm a comparable EPS basis; valuation growth therefore stays at 0%.
Not enough years of gross-margin data to score pricing power.
Median ROIC -42.4%, above the 12% hurdle in 0% of years.
Net cash position — no leverage risk.
Owner earnings changed trend unclear over up to the ten most recent annual observations.
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.
Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.
Score records captured Jul 26, 2026.
FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY
Missing a usable price or zero-growth estimate: ANF, BKNG.
Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
Across the filed record, revenue grew from $5.3M (FY2018) to $53.7M (FY2025) — about 39.1% a year compounded over 7 years.
ROIC is not available for the latest filed year, FY2025. Across the full 3-year measurable filed record, median ROIC was −42.4%. Over the v3 recent window (3 measurable filed years), median ROIC was −42.4%. The Returns on Capital filter above scores it 0/100.
QTTB's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Not disclosed in QTTB’s filings for these years — we don’t estimate it.
Gaps in a line mean that item isn’t in QTTB’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Flagship explainer
Q32 Bio Inc.'s filing does not supply enough comparable lines for a truthful flow chart — here's what is filed:
| Filed line | Value | % of revenue | Source |
|---|---|---|---|
| $53.7M | 100% |
| |
| $16.9M | 31% |
| |
| Income before tax | $29.8M | 55% |
|
| Income tax | $0 | 0% |
|
| $29.8M | 55% |
|
Flagship explainer
Q32 Bio Inc.'s filing tags don't support a full breakdown — here's what is filed:
| Filed line | Value | % of assets | Source |
|---|---|---|---|
| Total assets | $61.8M | 100% |
|
| Cash and equivalents | $48.3M | 78% |
|
| Stockholders’ equity | $42M | 68% |
|
Flagship explainer
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $29.8M | FY2025 |
| |
| Income before tax | $29.8M | FY2025 |
|
| Operating income | $16.9M | FY2025 |
|
| $53.7M | FY2025 |
| |
| Ending assets | $61.8M | FY2025 |
|
| Beginning assets | $92.3M | FY2024 |
|
| $42M | FY2025 |
| |
| $5.7M | FY2024 |
|
Flagship explainer
Q32 Bio Inc.’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:
| Filed line | Value | % of cash from operations | Source |
|---|---|---|---|
| Cash from operations | −$33.5M | −100% |
|
| Depreciation and amortization | $391000 | 1% |
|
Curated 19-manager tier
Delayed public 13F reports for 2026-Q1—not live positions, trades, or recommendations.
0 holding0 exited0 not holding0/19 resolved19 unavailable
| Manager | Reported position | Quarter-over-quarter | Filing accession |
|---|---|---|---|
| Abrams Capital | Unavailable | Comparison unavailable | Filing unavailable |
| Akre Capital | Unavailable | Comparison unavailable | Filing unavailable |
| Baupost Group | Unavailable | Comparison unavailable | Filing unavailable |
| Berkshire Hathaway | Unavailable | Comparison unavailable | Filing unavailable |
| Brave Warrior Advisors | Unavailable | Comparison unavailable | Filing unavailable |
| Dodge & Cox | Unavailable | Comparison unavailable | Filing unavailable |
| First Eagle | Unavailable | Comparison unavailable | Filing unavailable |
| Fundsmith | Unavailable | Comparison unavailable | Filing unavailable |
| Gardner Russo & Quinn | Unavailable | Comparison unavailable | Filing unavailable |
| Gates Foundation Trust | Unavailable | Comparison unavailable | Filing unavailable |
| Mairs & Power | Unavailable | Comparison unavailable | Filing unavailable |
| Markel / Markel-Gayner | Unavailable | Comparison unavailable | Filing unavailable |
| Oakmark / Harris Associates | Unavailable | Comparison unavailable | Filing unavailable |
| Pershing Square | Unavailable | Comparison unavailable | Filing unavailable |
| Polen Capital | Unavailable | Comparison unavailable | Filing unavailable |
| Sequoia / Ruane Cunniff | Unavailable | Comparison unavailable | Filing unavailable |
| Southeastern Asset Management | Unavailable | Comparison unavailable | Filing unavailable |
| Tweedy, Browne | Unavailable | Comparison unavailable | Filing unavailable |
| Yacktman Asset Management | Unavailable | Comparison unavailable | Filing unavailable |
Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.
Flagship explainer
Records still being gathered — partial as of retrieval Aug 11, 2026.
Partial coverage: the incomplete Form 4 walk cannot establish no activity, an activity date, or zero counts.
Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.
Records still being gathered — partial as of retrieval Aug 11, 2026.
Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.
No reported Form 4 rows were captured for QTTB; the incomplete walk cannot establish zero activity, zero counts, or a negative cluster result.
A filing source-event date will appear when a Form 4 row is captured.
Retrieved .
#230 of 728 scored Healthcare companies, ranked by Moat Score.
Compare QTTB with its nearest peers →All Healthcare companies on the Index →